Trial Profile
A Multicenter Cohort Study Investigating the Consequences of Delayed Trastuzumab Treatment on Clinical Outcomes in Patients with HER2-Positive Early Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Early breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 11 Oct 2017 New trial record
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.